Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of “Hold” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has received an average rating of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.75.

A number of equities research analysts have recently weighed in on IPSC shares. Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Mizuho began coverage on Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of the company. Versant Venture Management LLC acquired a new stake in shares of Century Therapeutics during the first quarter worth about $27,495,000. Commodore Capital LP purchased a new position in shares of Century Therapeutics in the 1st quarter valued at approximately $19,652,000. BlackRock Inc. acquired a new position in shares of Century Therapeutics in the second quarter valued at approximately $19,825,000. Seven Fleet Capital Management LP acquired a new stake in shares of Century Therapeutics during the second quarter worth $10,652,174. Finally, Trails Edge Capital Partners LP acquired a new position in Century Therapeutics in the 2nd quarter valued at $10,130,674. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Stock Up 1.1%

Shares of IPSC opened at $1.88 on Friday. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04. The company has a market capitalization of $340.41 million, a PE ratio of -2.02 and a beta of 1.59. The stock has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $2.22.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). As a group, equities analysts anticipate that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells.

Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies.